DarioHealth's Digital Diabetes Platform to be Made Available to 4.6 Million Customers at Giant Eagle, One of America's Largest Supermarket Chains

    Millions of Customers Will Be Able to Sign Up for Online Education and Rewards through the DarioHealth Blood Glucose Monitoring System and Smartphone Application.

    Nov 12, 2018

    CAESAREA, Israel, Nov. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has signed an agreement for the rollout of a Digital Diabetes Education and Rewards Program, powered by Dario, to Giant Eagle's consumers through the pharmacy's 214 locations. Giant Eagle is ranked among the top 40 on Forbes magazine's list of largest private corporations in the U.S. It is one of the country's largest food retailers and distributors with approximately $8.9 billion in annual sales.

    DarioHealth Logo

    DarioHealth's Dario Blood Glucose Monitoring System will be available to Giant Eagle's estimated 4.6 million customers served annually. Giant Eagle customers who enroll in and use the Dario system will receive diabetes education content through the app, as well as rewards related to better management of their diabetes.

    Jim Tsipakis, Senior Vice President, Pharmacy at Giant Eagle commented, "Giant Eagle has been an innovator and pioneer in the supermarket business since its founding in 1931. We continuously look to integrate best-of-breed technologies to improve our patients' health and their quality of life. We are excited to offer the benefits of digital healthcare to our patients through DarioHealth's platform."

    Tracy DeLucia, Senior Manager, Pharmacy Marketing, at Giant Eagle added, "When evaluating how we can better serve our patients living with diabetes, DarioHealth's product presented itself as a clear choice because it empowers the user with knowledge that is personalized and real time. Their app has robust tracking and reporting capabilities as well as alerts, messages, content and reminders to help patients stay adherent with testing.

    As a supermarket and a pharmacy, our goal is to have our patients thrive through healthy choices made both in the food aisle and in the pharmacy with the best technologies to monitor and treat their health condition."

    "This marks DarioHealth's largest product rollout agreement through a U.S. retailer to date. Our North America commercialization team is working hard to expand access to DarioHealth's digital health management solutions for the benefit of all North Americans. We are committed to empowering people living with chronic conditions with the knowledge they need to improve quality of life," stated Olivier Jarry, President and Chief Commercial Officer of DarioHealth.

    About DarioHealth Corp.
    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

    About Giant Eagle
    Founded in 1931, Giant Eagle is one of the 40 largest privately-held and family-operated companies in the USA.

    Giant Eagle serves more than five million customers annually through nearly 400 retail locations in Pennsylvania, Ohio, West Virginia and Maryland. Giant Eagle is based in Pittsburgh, PA.

    Giant Eagle Corporate Facts

    Cautionary Note Regarding Forward-Looking Statements
    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the benefits of it agreement with Giant Eagle, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact:
    Joao Mendes-Roter
    VP Marketing
    joao@mydario.com
    + 1-347-767-4220

    SOURCE DarioHealth Corp.


    print email rss